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Background: Characterization of combination effects of chemotherapy drugs with carbon ions in comparison to
photons in vitro.
Methods: The human colon adenocarcinoma cell line WiDr was tested for combinations with camptothecin,
cisplatin, gemcitabine and paclitaxel. In addition three other human tumour cell lines (A549: lung, LN-229: glioblast-
oma, PANC-1: pancreas) were tested for the combination with camptothecin. Cells were irradiated with photon
doses of 2, 4, 6 and 8 Gy or carbon ion doses of 0.5, 1, 2 and 3 Gy. Cell survival was assessed using the clonogenic
growth assay. Treatment dependent changes in cell cycle distribution (up to 12 hours post-treatment) were mea-
sured by FACS analysis after propidium-iodide staining. Apoptosis was monitored for up to 36 hours post-treatment
by Nicoletti-assay (with qualitative verification using DAPI staining).
Results: All cell lines exhibited the well-known increase of killing efficacy per unit dose of carbon ion exposure,
with relative biological efficiencies at 10% survival (RBE10) ranging from 2.3 to 3.7 for the different cell lines. In
combination with chemotherapy additive toxicity was the prevailing effect. Only in combination with gemcitabine
or cisplatin (WiDr) or camptothecin (all cell lines) the photon sensitivity was slightly enhanced, whereas purely
independent toxicities were found with the carbon ion irradiation, in all cases. Radiation-induced cell cycle changes
displayed the generally observed dose-dependent G2-arrest with little effect on S-phase fraction for all cell lines for
photons and for carbon ions. Only paclitaxel showed a significant induction of apoptosis in WiDr cell line but
independent of the used radiation quality.
Conclusions: Combined effects of different chemotherapeutics with photons or with carbon ions do neither
display qualitative nor substantial quantitative differences. Small radiosensitizing effects, when observed with
photons are decreased with carbon ions. The data support the idea that a radiochemotherapy with common drugs
and carbon ion irradiation might be as feasible as respective photon-based protocols. The present data serve as an
important radiobiological basis for further combination experiments, as well as clinical studies on combination treat-
ments.
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Today the combined radiochemotherapy with photons is
a well-established part of interdisciplinary tumour treat-
ment for many tumour entities [1]. The molecular and
cellular fundamentals as well as the clinical implications
are well known for combined radiochemotherapy with
photons and are subjects to further preclinical and clin-
ical investigations. Heavy ion radiotherapy offers distinct
biological and physical characteristics for a precise
tumour treatment with simultaneous protection of nor-
mal tissues: the inverted dose profile with low dose
deposition in the entry channel and high dose deposition
in the so called Bragg peak leads to normal tissue pro-
tection and reduction of the integral dose to the patient.
Heavy ions also produce severe radiation damage within
the beam track leading to a higher relative biological
effectiveness (RBE) for heavy ions in comparison to pho-
tons [2-4]. Most likely the higher efficiency in cell-killing
of heavy ions is based on complex and/or densely spaced
DNA double-strand breaks which are difficult to repair
for the cells [5,6]. The clinical use of heavy ion radio-
therapy is subject of several clinical investigations [7,8].
Combined radiochemotherapy with photons is well-
established in the clinical practice based on various pre-
clinical and clinical investigations, however, there is only
little data for the combination of chemotherapy with
heavy ions. Due to the different radiobiological effects of
heavy ions especially to the impact on cell cycle control,
the known combination effects from photons in combin-
ation with chemotherapies of different working mecha-
nisms may differ from the combination effects from
heavy ions. In vitro investigations by Kitabayashi and
colleagues evaluated carbon ion irradiation in combination
with different chemotherapies in oesophageal squamous
cell carcinoma cells. They found additive effects for all
combinations except for docetaxel which showed synergis-
tic combination effects [9]. Previous in vitro investigations
for combined radiochemotherapy with carbon ions in glio-
blastoma cells showed an RBE ranging between 3.3 and
3.9 depending on survival level and dose. Combination
with chemotherapies of different mechanisms of action
demonstrated additive effects with dominant effects
produced by paclitaxel and camptothecin [10].
An expansion of the clinical implication of heavy ion
radiotherapy must include the combination with chemo-
therapies. The ambition of the present analysis is to
evaluate the combination effects of carbon ion irradi-
ation when combined with different chemotherapies in a
human adenocarcinoma cell line which was previously
used in our lab to support radiochemotherapy studies.
In addition, since the drug camptothecin revealed some
indications of radiosensitization, three other cell lines
(glioblastoma, lung, pancreas) were tested for combin-
ation with camptothecin as well.Methods
Cell culture
The human tumour cell lines A549 (lung), LN-229 (glio-
blastoma), PANC-1 (pancreas) and WiDr (colon) were
obtained from the American Type Culture Collection
(ATCC, Manassas, VA, USA). The cells were cultured in
DMEM supplemented with 10% foetal calf serum (FCS),
respectively in RPMI 1640 supplemented with 10% foetal
calf serum (PANC-1). They were maintained in culture
at 37°C in humidified air with 6% CO2.Photon irradiation
Photon irradiation was performed as single dose exposure
to photon doses of 2, 4, 6 and 8 Gy at room temperature.
Photons were delivered by a biological irradiator (Preci-
sion X-Ray, North Branford, CT, USA). Photons were de-
livered at 320 kV and 12.5 mA with an averaged dose rate
of 1 Gy per minute.Carbon ion irradiation
Carbon ion irradiation was performed at the Heidelberg
Ion Therapy Centre (HIT) using a horizontal beamline
with rasterscanning technique. To obtain clinically rele-
vant parameters in cell irradiation the dose was delivered
as an extended Bragg peak with 103 keV/μm (dose aver-
aged LET). The cell monolayers were irradiated in the
middle of the extended Bragg peak adjusted by using a
3 cm acrylic shield. Single carbon ion doses of 0.5, 1, 2
and 3 Gy were applied with an averaged dose rate of
0.5 Gy per minute.Chemotherapeutic treatment
All cell lines were treated with chemotherapy concentra-
tions at medium toxicity level (approximately 50% clono-
genic survival) for 4 hours followed by a medium change
prior to irradiation. This is an exposure scheme firmly
established in our laboratory to limit drug exposure time
because active clearance mechanisms as present in the
whole organism are absent in the culture flask. Of course
a direct simulation of the clinical situation is not possible.
WiDr cell line was tested for camptothecin (Enzo Life Sci-
ences GmbH, Lörrach, Germany), cisplatin, gemcitabine
and paclitaxel (all obtained from the pharmacy of Univer-
sity Hospital Heidelberg), all other cell lines were tested
for combination with camptothecin.
For all substances, dose–response-relationships were
generated for single-agent treatment. Following drug
concentrations were chosen for combination experi-
ments: camptothecin at 80 nM (A549), 75 nM (LN-229),
25 nM (PANC-1) and 100 nM (WiDr), cisplatin at
2 μM, gemcitabine at 70 nM and paclitaxel at 25 nM.
Table 1 RBE10 values for different cell lines
WiDr A549 LN-229 PANC-1
no drug 3.1 ± 0.7 3.6 ± 0.8 2.7 ± 0.5 2.4 ± 0.4
camptothecin 2.6 ± 0.3 2.8 ± 0.5 2.5 ± 1.1 2.2 ± 0.2
cisplatin 2.6 ± 0.01 - - -
gemcitabine 3.1 ± 0.1 - - -
paclitaxel 3.2 ± 0.5 - - -
Mean values of relative biological efficiencies at 10% survival (RBE10) (plus
standard deviations) for irradiation alone or in combination with
chemotherapy drugs.
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The effects of single and double treatment on cell sur-
vival were evaluated using the clonogenic growth assay
representing the radiobiological gold standard. Due to
the fact that the final cell death may occur only after
additional cell divisions the clonogenic survival is an im-
portant marker of cell survival after treatment with ion-
izing irradiation and antitumour reagents. All cell lines
were grown under standard conditions. For analysing
the effects of photon or carbon ion irradiation alone or
in combination with chemotherapy on clonogenic sur-
vival, increasing numbers of cells were plated in 25 cm2
flasks (Sarstedt, Nümbrecht, Germany). After an attach-
ment period cells were exposed to specific treatment
and kept in the incubator for 10–14 days after which
they were stained with crystal violet (Serva Electrophor-
esis GmbH, Heidelberg, Germany). Colonies were
counted by microscopic inspection and only colonies
with at least 50 cells were counted. Plating efficiencies
and survival fractions were calculated. Each experiment
was performed in triplicates and was repeated at 3 differ-
ent days. Mean values and standard deviations were only
calculated from independent experiments. Analysis of
statistical significance was performed using the t-test. In
combination experiments an approach was invoked
utilising the criteria of additivity described by Steel and
Peckham [11]. The following definitions were used for
the description of drug-radiation interactions: independ-
ent toxicity denotes the effect of the combination of two
agents where total effect is a product of the effects of
single agents. This mechanism needs no interaction
between drugs and radiation, or their biological effects.
The term additivity and supra-additivity according to
Steel and Peckham (see above) is defined for a range of
combination toxicities. This range is restricted by the
dose–response curve of radiation and the isoeffect curve
of radiation on the effect level of chemotherapy, alone.
Dose–response curves located within this range repre-
sent additive effects, when exceeding this range they
describe supra-additive effects (or synergism).
Cell cycle analysis and monitoring of apoptosis
Treatment dependent changes in cell cycle distribution
were analysed at 4 different time points: at the beginning
of chemotherapy treatment, directly post-irradiation, 8
and 12 hours post-irradiation. After trypsinization the
cells were washed and fixed in 70% ethanol. Fixed cells
were centrifuged, washed and incubated in RNAse
and propidium iodide prior to measurement of DNA-
content using a FACScan flow cytometer (Becton
Dickinson, Heidelberg, Germany) [12]. Each experiment
was repeated at 3 different days. Mean values and stand-
ard deviations were only calculated from independent
experiments.Apoptosis was monitored at 12, 24 and 36 hours post-
irradiation by Nicoletti-assay [13]. Trypsinized cells were
washed and fixed in 70% ethanol. Fixed cells were cen-
trifuged, washed and incubated in a hypotonic fluoro-
chrome solution (PI 50 μg/ml in 0.1% sodium citrate
plus 0.1% Triton X-100) in the dark overnight before
flow-cytometric analysis. Each experiment was repeated
at 3 different days. Mean values and standard deviations
were only calculated from independent experiments.
Qualitative verification was performed using DAPI stain-
ing and microscopic inspection.
Results
Clonogenic survival and determination of RBE
The clonogenic survival was calculated for all used cell
lines for increasing doses of photon or carbon ion irradi-
ation. All cell lines exhibited the well-known increase of
killing efficacy per unit dose of carbon ion exposure
leading to a steeper dose–response-relationship for
carbon ions compared to photons. The strongest effect
was seen for A549 cell line.
From these values we calculated the relative biological
efficiencies at 10% survival level for each cell line
(Table 1). These RBE10 values range from 2.3 to 3.7
depending on the cell line.
Evaluation of cytotoxic effect of combination therapies
Combination experiments of 4 chemotherapeutic drugs
camptothecin, cisplatin, gemcitabine and paclitaxel with
both radiation qualities for WiDr cell line were per-
formed (Figure 1). For generation of the survival curves
within each independent experiment, PE-values mea-
sured in triplicate for each treatment condition and the
averaged values were normalized to the respective num-
ber of untreated sample. Respective PE-values in the
combination experiments were normalized to a drug
control yielding surviving fractions displayed in the
graphical representation. Slightly enhanced photon sen-
sitivity was found in combination with camptothecin,
cisplatin and gemcitabine, whereas all other combina-
tions showed only independent toxicities.
For generation of the survival curves of combination
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Figure 1 Combination experiments of 4 chemotherapeutic drugs in WiDr cell line, as indicated. Clonogenic radiation survival of log-phase
WiDr cells. Cells were irradiated with photons or carbon ions only or directly after a 4-hour treatment with camptothecin, cisplatin, gemcitabine
or paclitaxel and a following medium change. Data points are mean values (plus standard deviations) from three independent experiments.
The survival curves were derived from a fit of the linear-quadratic survival expression to the data.
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slightly enhanced photon sensitivity for all cell lines in
combination with camptothecin, whereas purely inde-
pendent toxicities were found with carbon ions leading to
lower RBE10-values for combination treatment (Table 1).
Cell cycle distribution after irradiation and chemotherapy
treatment
All cell lines showed the prevailing dose-dependent G2-
arrest after photon and carbon ion irradiation while the
maximum for carbon ions was not reached in the ana-
lysed time. For all cell lines a cell cycle delay after car-
bon ion irradiation was observed also in combination
therapy. In combination with camptothecin a drug-
specific halt in S-phase up to 8 hours post-irradiation
with transition into the G2-arrest was seen for all cell
lines. Combination with gemcitabine showed a drug-
specific halt in S-phase for more than 12 hours post-
irradiation with delayed occurrence of G2-arrest for
WiDr cell line. In combination with cisplatin no specificinfluence on cell cycle distribution was visible for WiDr
cell line. Paclitaxel showed a stronger increase in G2/M-
phase fraction in combination compared to irradiation
alone (Figures 3, 4).
Treatment specific apoptosis after irradiation and
chemotherapy treatment
All cell lines showed no significant induction of apop-
tosis neither for irradiation alone nor for combination
with camptothecin. For WiDr cell line only paclitaxel
showed a significant induction of apoptosis but inde-
pendent of the used radiation quality (Figure 5).
Discussion
Our experiments evaluated the combination of different
chemotherapeutic substances with photon and carbon
ion irradiation with respect to cell survival in different
human tumour cell lines. A slightly enhanced photon
sensitivity was found for the combination with camp-
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Figure 2 Combination experiments of camptothecin in 4 different cell lines, as indicated. Clonogenic radiation survival of 4 different log-
phase tumour cell lines. Cells were irradiated with photons or carbon ions only or directly after a 4-hour treatment with camptothecin and a
following medium change. Data points are mean values (plus standard deviations) from three independent experiments. The survival curves were
derived from a fit of the linear-quadratic survival expression to the data. Note, that the WiDr panel is the same as in Figure 1 for camptothecin
but now in the changed context.
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Figure 3 Cell cycle distribution (as indicated) of WiDr cells treated with 8 Gy photons and 4 different chemotherapy drugs. Change of
cell cycle distribution of log-phase WiDr cells. After a 4-hour treatment with camptothecin, cisplatin, gemcitabine or paclitaxel and a following
medium change cells were irradiated with 8 Gy photons. Cell cycle distribution was measured by flow cytometry after propidium iodide staining
up to 12 hours post-irradiation. Data points represent mean values (plus standard deviations) from three independent measurements.
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Figure 4 Cell cycle distribution (as indicated) of WiDr cells treated with 3 Gy carbon ions and 4 different chemotherapy drugs. Change
of cell cycle distribution of log-phase WiDr cells. After a 4-hour treatment with camptothecin, cisplatin, gemcitabine or paclitaxel and a following
medium change cells were irradiated with 3 Gy carbon ions. Cell cycle distribution was measured by flow cytometry after propidium iodide
staining up to 12 hours post-irradiation. Data points represent mean values (plus standard deviations) from three independent measurements.
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showed only independent toxicities.
Until now, few data is available on the combination of
chemotherapy and high-LET particle beams, such as
carbon ion radiotherapy.
Camptothecin acts by binding to and stabilizing of the
covalent binary complex DNA-topoisomerase I leading to
inhibition of religation of the cleaved strand and DNA
double-strand-breaks [14]. Today, two camptothecin ana-
logues are in clinical use: topotecan and irinotecan [14,15].
Djuzenova et al. [16] investigated the combined treatment
with camptothecin and ionizing radiation in five glioma
































Figure 5 Treatment specific apoptosis of WiDr cells at 36 hours post-
gemcitabine or paclitaxel followed by a medium change and irradiation w
measured by flow cytometry using Nicoletti-assay. Data points represent m
measurements.pretreatment only in two of five cell lines. Rave-Fränk et al.
[17] showed radiosensitization for photon irradiation in
WiDr cell line after 24 h pretreatment with topotecan.
These results are conclusive to the effects we found.
The antitumour activity of cisplatin is attributed to the
kinetics of its chloride ligand displacement reactions
leading to DNA crosslinking activities. DNA crosslinks
inhibit replication, transcription and other nuclear func-
tions and arrest cancer cell proliferation and tumour
growth. A number of additional properties of cisplatin
are emerging, including activation of signal transduction
pathways leading to apoptosis [18]. Today cisplatin, usu-





















irradiation. Cells were treated for 4 hours with camptothecin, cisplatin,
ith 4 or 8 Gy photons or 1 or 3 Gy carbon ions. Apoptosis was
ean values (plus standard deviations) from three independent
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as second-line treatment [19]. In vitro studies for com-
bination treatment with cisplatin and ionizing radiation
showed differential results. Flentje et al. [20] observed
additive effects for four human cell lines independent of
simultaneous or sequential cisplatin exposure. Geldof
et al. [21,22] found supra-additive treatment effects of
cisplatin with radiotherapy in prostate cancer cell lines.
Zhang et al. [23] investigated concurrent cetuximab,
cisplatin and radiation in seven HNSCC cell lines. Only
one cell line showed supra-additive effects for the com-
bination of cisplatin and radiation, all others showed
only additive effects. Our experiments showed also addi-
tive effects for combination of cisplatin and photon
irradiation but only independent toxicities for the
combination with carbon ion irradiation.
Gemcitabine is converted intracellularly to the active
metabolites difluorodeoxycytidine di- and triphosphate
(dFdCDP and dFdCTP). dFdCDP inhibits ribonucleotide
reductase, thereby decreasing the deoxynucleotide pool
available for DNA synthesis. dFdCTP is incorporated
into DNA, resulting in DNA strand termination and
apoptosis [24]. Gemcitabine has wide a spectrum of ac-
tivity against solid tumours and is currently under inves-
tigation in many clinical trials. Latz et al. [25] could
show a supra-additive effect for the combination of
gemcitabine and photon irradiation in WiDr cells when
irradiation was performed at the end of gemcitabine
exposure (2 h). For all other points of time only additive
effects were observed. They could also show an S-phase-
specific radiosensitization by gemcitabine for serum
stimulated WiDr cells. These results were confirmed by
Harrabi et al., which could also show an S-phase-specific
radiosensitization by gemcitabine for synchronized WiDr
cells when irradiated with carbon ions whereas log-
phase cells only showed additive effects [unpublished
data; personal communication by SB Harrabi]. Our
experiments also showed slightly enhanced photon
sensitivity in log-phase WiDr cells when pretreated with
gemcitabine (4 h). When irradiated with carbon ions
these cells showed only independent toxicities. These
differences between photon and carbon ion irradiation
might be explained by the fact that the effectiveness of
carbon ions is less cell-cycle-dependent.
Paclitaxel binds to β-tubulin, stabilizes the micro-
tubule and thereby inhibits depolymerization. This
disrupts the normal dynamic reorganization of the
microtubule network required for mitosis and cell
proliferation and results in the arrest of cells in the
G2M-phase at passing from metaphase to anaphase.
Drug-blocked cells may eventually exit mitosis, often
aberrantly. Mitotically blocked or mitotically slowed cells
eventually die by apoptosis [26-28]. The G2M-phase is
the most radiosensitive phase of the cell cycle and thuspaclitaxel should act as a potent radiosensitizer. Tishler
et al. [29] could show a more than additive effect after
24 hours of 10 nM paclitaxel exposure and subsequent
photon irradiation in G18 cell line. At this point of time
nearly 100% of cells were in G2M-phase. The same effect
was demonstrated by Wenz et al. [30]: photon irradi-
ation given 6 hours after 0.3 μM paclitaxel for 2 hours
showed a considerable increase in radiosensitivity. When
irradiation was given 4 hours after the beginning of pacli-
taxel exposure radiosensitivity was slightly reduced. In
conclusion maximal radiosensitization of paclitaxel was
seen when irradiation was given at the time of maximal
G2M accumulation of cells. They also showed that p53wt
TK6 cells were permanently blocked in G2M whereas
p53mut WTK1 cells were only transiently blocked, sug-
gesting a function of p53 in the response to paclitaxel. In
our experiments WiDr cells showed only independent
toxicities regardless of the used radiation quality. WiDr
cells were irradiated after 4 hours incubation with 25 nM
paclitaxel. At this point of time the G2M fraction was
about 20% and about 40% of cells were in S-phase. This
could be a possible explanation for the absence of radio-
sensitization of paclitaxel. Another hypothesis for the
absence of radiosensitization when combined with carbon
ions is a possible reduction of the cross-section area at
maximal G2M accumulation by beginning chromatin con-
densation in the early metaphase. For evaluation of this
hypothesis further experiments are required.
WiDr cells showed a significant induction of apoptosis
after treatment with paclitaxel independent of the used
radiation quality, suggesting that apoptosis is induced by
paclitaxel. As WiDr cell line is p53 mutated the induction
of apoptosis by paclitaxel must be independent of p53.
A recently published study by Combs et al. [10] evalu-
ated the combination of carbon ion radiotherapy with
chemotherapy in U87 cell line and showed similar
results compared to ours.
In our experiments a cell cycle delay was seen after
carbon ion irradiation alone and in combination with
different chemotherapeutics. Scholz et al. [31] could
show a prolongation of delays with increasing LET while
a large fraction of cells remained in S or G2M phase for
up to 48 h or longer after irradiation. Already early
investigations of Lücke-Huhle et al. [32] in V79 cell line
revealed high-LET particle beams to be much more ef-
fective in causing a G2M block than low-LET radiation,
and the RBE values for G2M block were much higher
than the RBEs for survival. This is consistent with our
findings although the maximum G2M accumulation after
carbon ion irradiation was not reported in the measured
time points.
This manuscript presents an extensive evaluation of
the combination effects of carbon ions and chemother-
apy drugs of different mechanisms of action. Therefore
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formation for subsequent preclinical as well as clinical
applications, leading to the conclusion that when such
substances are combined with carbon ions no specific
reductions in dosing with respect to cytotoxicity in the
radiation area must be undertaken compared to com-
bined treatments with photons.
Conclusions
Combined effects of different chemotherapeutics with
photons or with carbon ions with respect to in vitro
survival do neither display qualitative nor substantial
quantitative differences. Small increased effects above
independent toxicities, when observed with photons are
decreased with carbon ions. The data support the idea that
a radiochemotherapy with common drugs and carbon ion
irradiation might be as feasible as respective photon-based
protocols. The present data serve as an important radio-
biological basis for further combination experiments, as
well as clinical studies on combination treatments.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
FS, JD, SEC and KJW designed and planned the experiments. FS performed
the experiments. SB and TH performed radiation therapy treatment planning
and application. FS and KJW wrote the manuscript and made the graphical
illustrations. All co-authors approved the manuscript.
Acknowledgements
This work was funded by the Deutsche Forschungsgemeinschaft (DFG),
Klinische Forschergruppe Schwerionentherapie (KFO 214).
We thank Ludmilla Frick and Sylvia Trinh for expert technical assistance with
the experiments.
Author details
1Department of Radiation Oncology, University Hospital Heidelberg, Im
Neuenheimer Feld 400, Heidelberg 69120, Germany. 2Heidelberg Ion Therapy
Centre (HIT), Im Neuenheimer Feld 450, Heidelberg 69120, Germany.
Received: 19 June 2013 Accepted: 28 October 2013
Published: 6 November 2013
References
1. Bartelink H, Schellens JHM, Verheij M: The combined use of radiotherapy
and chemotherapy in the treatment of solid tumours. Eur J Cancer 2002,
38:216–222.
2. Scholz M, Kraft G: Track structure and the calculation of biological effects
of heavy charged particles. Adv Space Res 1996, 18:5–14.
3. Krämer M, Weyrather WK, Scholz M: The increased biological effectiveness
of heavy charged particles: from radiobiology to treatment planning.
Technol Cancer Res Treat 2003, 2:427–436.
4. Kraft G: The radiobiological and physical basis for radiotherapy with
protons and heavier ions. Strahlenther Onkol 1990, 166:10–13.
5. Blakely EA, Kronenberg A: Heavy-ion radiobiology: new approaches to
delineate mechanisms underlying enhanced biological effectiveness.
Radiat Res 1998, 150:S126–S145.
6. Weber KJ, Flentje M: Lethality of heavy ion-induced DNA double-strand
breaks in mammalian cells. Int J Radiat Biol 1993, 64:169–178.
7. Mizoe J-E, Hasegawa A, Jingu K, Takagi R, Bessyo H, Morikawa T, Tonoki
M, Tsuji H, Kamada T, Tsujii H, Okamoto Y: Results of carbon ion
radiotherapy for head and neck cancer. Radiother Oncol 2012,
103:32–37.8. Combs SE, Kieser M, Rieken S, Habermehl D, Jäkel O, Haberer T,
Nikoghosyan A, Haselmann R, Unterberg A, Wick W, Debus J:
Randomized phase II study evaluating a carbon ion boost applied
after combined radiochemotherapy with temozolomide versus a
proton boost after radiochemotherapy with temozolomide in
patients with primary glioblastoma: the CLEOPATRA trial.
BMC Cancer 2010, 10:478.
9. Kitabayashi H, Shimada H, Yamada S, Yasuda S, Kamata T, Ando K, Tsujii
H, Ochiai T: Synergistic growth suppression induced in esophageal
squamous cell carcinoma cells by combined treatment with
docetaxel and heavy carbon-ion beam irradiation. Oncol Rep 2006,
15:913–918.
10. Combs SE, Zipp L, Rieken S, Habermehl D, Brons S, Winter M, Haberer T,
Debus J, Weber K-J: In vitro evaluation of photon and carbon ion radio-
therapy in combination with chemotherapy in glioblastoma cells.
Radiat Oncol 2012, 7:9.
11. Steel GG, Peckham MJ: Exploitable mechanisms in combined
radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol
Biol Phys 1979, 5:85–91.
12. Krishan A: Rapid flow cytofluorometric analysis of mammalian cell cycle
by propidium iodide staining. J Cell Biol 1975, 66:188–193.
13. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C: A rapid
and simple method for measuring thymocyte apoptosis by
propidium iodide staining and flow cytometry. J Immunol Methods
1991, 139:271–279.
14. Thomas CJ, Rahier NJ, Hecht SM: Camptothecin: current perspectives.
Bioorg Med Chem 2004, 12:1585–1604.
15. Sriram D, Yogeeswari P, Thirumurugan R, Bal TR: Camptothecin and its
analogues: a review on their chemotherapeutic potential. Nat Prod Res
2005, 19:393–412.
16. Djuzenova CS, Güttler T, Berger S, Katzer A, Flentje M: Differential response
of human glioblastoma cell lines to combined camptothecin and
ionizing radiation treatment. Cancer Biol Ther 2008, 7:364–373.
17. Rave-Fränk M, Glomme S, Hertig J, Weiss E, Pradier O, Hess CF, Virsik-Köpp P,
Schmidberger H: Combined effect of topotecan and irradiation on the
survival and the induction of chromosome aberrations in vitro.
Strahlenther Onkol 2002, 178:497–503.
18. Boulikas T, Vougiouka M: Cisplatin and platinum drugs at the molecular
level: (Review). Oncol Rep 2003, 10:1663–1682.
19. Boulikas T, Vougiouka M: Recent clinical trials using cisplatin, carboplatin
and their combination chemotherapy drugs (review). Oncol Rep 2004,
11:559–595.
20. Flentje M, Eble M, Haner U, Trinh S, Wannenmacher M: Additive effects of
cisplatin and radiation in human tumor cells under oxic conditions.
Radiother Oncol 1992, 24:60–63.
21. Geldof AA, Slotman BJ: Radiosensitizing effect of cisplatin in prostate
cancer cell lines. Cancer Lett 1996, 101:233–239.
22. Geldof AA, Kruit A, Newling DW, Slotman BJ: Synergism between cisplatin
and radiotherapy in an in vitro prostate tumor cell line. Anticancer Res
1999, 19:505–508.
23. Zhang N, Erjala K, Kulmala J, Qiu X, Sundvall M, Elenius K, Grénman R:
Concurrent cetuximab, cisplatin, and radiation for squamous cell
carcinoma of the head and neck in vitro. Radiother Oncol 2009,
92:388–392.
24. Scaife J, Kerr D: Antimetabolites in cancer therapy. In Anticancer
therapeutics. Edited by Missailidis S. Oxford: Wiley-Blackwell; 2008:100–101.
25. Latz D, Fleckenstein K, Eble M, Blatter J, Wannenmacher M, Weber KJ:
Radiosensitizing potential of gemcitabine (2’,2’-difluoro-2’-deoxycy-
tidine) within the cell cycle in vitro. Int J Radiat Oncol Biol Phys 1998,
41:875–882.
26. Mollinedo F, Gajate C: Microtubules, microtubule-interfering agents and
apoptosis. Apoptosis 2003, 8:413–450.
27. Jordan MA, Wilson L: Microtubules as a target for anticancer drugs.
Nat Rev Cancer 2004, 4:253–265.
28. Gligorov J, Lotz JP: Preclinical pharmacology of the taxanes: implications
of the differences. Oncologist 2004, 9(Suppl 2):3–8.
29. Tishler RB, Geard CR, Hall EJ, Schiff PB: Taxol sensitizes human astrocytoma
cells to radiation. Cancer Res 1992, 52:3495–3497.
30. Wenz F, Greiner S, Germa F, Mayer K, Latz D, Weber KJ:
Radiochemotherapy with paclitaxel: synchronization effects and the role
of p53. Strahlenther Onkol 1999, 175(Suppl 3):2–6.
Schlaich et al. Radiation Oncology 2013, 8:260 Page 9 of 9
http://www.ro-journal.com/content/8/1/26031. Scholz M, Kraft-Weyrather W, Ritter S, Kraft G: Cell cycle delays induced by
heavy ion irradiation of synchronous mammalian cells. Int J Radiat Biol
1994, 66:59–75.
32. Lücke-Huhle C, Blakely EA, Chang PY, Tobias CA: Drastic G2 arrest in
mammalian cells after irradiation with heavy-ion beams. Radiat Res 1979,
79:97–112.
doi:10.1186/1748-717X-8-260
Cite this article as: Schlaich et al.: Comparison of the effects of photon
versus carbon ion irradiation when combined with chemotherapy
in vitro. Radiation Oncology 2013 8:260.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
